NovaBay Pharmaceuticals, Inc. (NBY) News
Filter NBY News Items
NBY News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
NBY News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest NBY News From Around the Web
Below are the latest news stories about NOVABAY PHARMACEUTICALS INC that investors may wish to consider to help them evaluate NBY as an investment opportunity.
NovaBay Pharmaceuticals (NBY) Upgraded to Buy: Here's WhyNovaBay Pharmaceuticals (NBY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
NovaBay Pharmaceuticals Announces the Further Adjournment of the Special Meeting of StockholdersEMERYVILLE, Calif., December 19, 2024--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) ("NovaBay" or the "Company") announces that its Reconvened Special Meeting of Stockholders held on December 18, 2024 has been adjourned until January 16, 2025 at 11:00 a.m. Pacific time to provide stockholders additional time to vote on Proposal One and Proposal Two. Both proposals received significant support based on the shares that have been voted by stockholders but have yet to reach the 50% threshold |
NovaBay CEO Letter to Stockholders Urges a FOR Vote at Upcoming Reconvened Special MeetingEMERYVILLE, Calif., December 09, 2024--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) ("NovaBay" or the "Company") announces that Chief Executive Officer Justin Hall has issued the following Letter to Stockholders: |
NovaBay Pharmaceuticals to Reconvene Special Meeting of Stockholders on December 18, 2024EMERYVILLE, Calif., November 22, 2024--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) ("NovaBay" or the "Company") announces that its Special Meeting of Stockholders held on November 22, 2024 has been adjourned until December 18, 2024 at 11:00 a.m. Pacific time to provide stockholders additional time to vote on Proposal One and Proposal Two. Both proposals received significant support based on the shares that have been voted by stockholders but have yet to reach the 50% threshold of favorab |
Prominent Independent Proxy Advisory Firm ISS Supports NovaBay Pharmaceuticals’ Proposals to Authorize the Sale of its Avenova BrandEMERYVILLE, Calif., November 15, 2024--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) ("NovaBay" or the "Company") announces that the largest institutional advisory firm, Institutional Shareholder Services (ISS), has recommended that NovaBay stockholders vote in favor of all of the Company’s proxy proposals, specifically to authorize and approve the sale of its eyecare business (the "Asset Sale Proposal") and approve the voluntary liquidation and dissolution of the Company (the "Dissolution |
NovaBay Pharmaceuticals Reports Third Quarter 2024 Financial ResultsEMERYVILLE, Calif., November 07, 2024--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) reports financial results for the three and nine months ended September 30, 2024. |
NovaBay Pharmaceuticals Accepts Revised Offer from PRN Physician Recommended Nutriceuticals, LLC and Enters into an Amendment to the Asset Purchase Agreement to Increase Purchase PriceEMERYVILLE, Calif., November 06, 2024--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) ("NovaBay" or the "Company") today announces that the Company has accepted a revised transaction proposal from PRN Physician Recommended Nutriceuticals, LLC ("PRN") to increase the base purchase price for the Company’s eyecare business from $9.5 million to $11.5 million. The Company has entered into an amendment (the "Amendment") to its previously announced Asset Purchase Agreement, dated September 19, 202 |
NovaBay Pharmaceuticals Board Determines Unsolicited Offer is Superior to Asset Purchase Agreement with PRN Physician Recommended Nutriceuticals, LLCEMERYVILLE, Calif., October 29, 2024--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) ("NovaBay" or the "Company") announces that the Company’s board of directors has determined that an unsolicited and non-binding offer from Refresh Acquisitions BidCo LLC ("Refresh") for an affiliate of Refresh to acquire the Company’s Avenova® brand and related assets is a "Superior Proposal" to the Company’s asset purchase agreement with PRN Physician Recommended Nutriceuticals, LLC ("PRN"). |
Acumen Health Holdings ("Acumen") to Acquire the Avenova brand from NovaBay PharmaceuticalsAcumen Health Holdings, LLC, a professionally recommended, consumer-preferred dietary supplements company focused on eye health and companion animals, announced today that its subsidiary, PRN Physician Recommended Nutriceuticals, LLC, has entered into a definitive asset purchase agreement to acquire the assets of the Avenova® brand (the "Brand") and business from NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) ("NovaBay"). The Brand offers several products for ocular health including cleansi |
NovaBay Pharmaceuticals Signs Definitive Agreement to Sell its Avenova AssetsEMERYVILLE, Calif., September 20, 2024--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) ("NovaBay" or the "Company") announces it has entered into a definitive asset purchase agreement (the "Agreement") with PRN Physician Recommended Nutriceuticals, LLC ("PRN") to sell the assets of its Avenova® brand and business for $9.5 million in cash. The transaction has been approved by the Company’s board of directors and is anticipated to close in the fourth quarter of 2024, subject to the satisfacti |